458 related articles for article (PubMed ID: 27461036)
21. Methods for Measuring ctDNA in Lymphomas.
Rossi D; Condoluci A; Spina V; Gaidano G
Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
[TBL] [Abstract][Full Text] [Related]
22. Liquid biopsy in tissue-born lymphomas.
Spina V; Rossi D
Swiss Med Wkly; 2019 Jan; 149():w14709. PubMed ID: 30673117
[TBL] [Abstract][Full Text] [Related]
23. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
Wu FT; Lu L; Xu W; Li JY
Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
[TBL] [Abstract][Full Text] [Related]
25. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
[TBL] [Abstract][Full Text] [Related]
26. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort.
Bohers E; Viailly PJ; Becker S; Marchand V; Ruminy P; Maingonnat C; Bertrand P; Etancelin P; Picquenot JM; Camus V; Menard AL; Lemasle E; Contentin N; Leprêtre S; Lenain P; Stamatoullas A; Lanic H; Libraire J; Vaudaux S; Pepin LF; Vera P; Tilly H; Jardin F
Blood Cancer J; 2018 Aug; 8(8):74. PubMed ID: 30069017
[TBL] [Abstract][Full Text] [Related]
27. Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas.
O'Malley DP; Auerbach A; Weiss LM
Arch Pathol Lab Med; 2015 Sep; 139(9):1094-107. PubMed ID: 25554969
[TBL] [Abstract][Full Text] [Related]
28. Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.
Zhao K; Zheng X; Liu X; Liu T; Ke Z; Zhu F; Wen Q; Xin B; Li Q; Zhang L
Oncologist; 2024 May; 29(5):e672-e680. PubMed ID: 38297976
[TBL] [Abstract][Full Text] [Related]
29. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.
Camus V; Sarafan-Vasseur N; Bohers E; Dubois S; Mareschal S; Bertrand P; Viailly PJ; Ruminy P; Maingonnat C; Lemasle E; Stamatoullas A; Picquenot JM; Cornic M; Beaussire L; Bastard C; Frebourg T; Tilly H; Jardin F
Leuk Lymphoma; 2016 Sep; 57(9):2171-9. PubMed ID: 26883583
[TBL] [Abstract][Full Text] [Related]
30. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
[TBL] [Abstract][Full Text] [Related]
31. Measurable Residual Disease Monitoring in Lymphoma.
Cuzzo B; Lipsky A; Cherng HJ
Curr Hematol Malig Rep; 2023 Dec; 18(6):292-304. PubMed ID: 37930608
[TBL] [Abstract][Full Text] [Related]
32. Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Naushad H; Bi C; Yu J; Bouska A; Rohr J; Chao W; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):73-88. PubMed ID: 26432520
[TBL] [Abstract][Full Text] [Related]
33. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
[No Abstract] [Full Text] [Related]
34. [Clinical Application of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
Chen XF; Wang M; Zhang F; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):638-642. PubMed ID: 33812444
[TBL] [Abstract][Full Text] [Related]
35. The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.
Camus V; Jardin F; Tilly H
Expert Rev Mol Diagn; 2017 Jun; 17(6):557-566. PubMed ID: 28415895
[TBL] [Abstract][Full Text] [Related]
36. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
[TBL] [Abstract][Full Text] [Related]
37. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
Alix-Panabières C; Pantel K
Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
[TBL] [Abstract][Full Text] [Related]
39. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
40. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
Kurtz DM; Soo J; Co Ting Keh L; Alig S; Chabon JJ; Sworder BJ; Schultz A; Jin MC; Scherer F; Garofalo A; Macaulay CW; Hamilton EG; Chen B; Olsen M; Schroers-Martin JG; Craig AFM; Moding EJ; Esfahani MS; Liu CL; Dührsen U; Hüttmann A; Casasnovas RO; Westin JR; Roschewski M; Wilson WH; Gaidano G; Rossi D; Diehn M; Alizadeh AA
Nat Biotechnol; 2021 Dec; 39(12):1537-1547. PubMed ID: 34294911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]